Humira (adalimumab) / AbbVie 
Welcome,         Profile    Billing    Logout  
 200 Diseases   176 Trials   176 Trials   22001 News 


12345678910111213...238239»
  • ||||||||||  Humira (adalimumab) / AbbVie
    Journal:  Transarterial Embolization for Refractory Ankle Synovitis in an Adult Patient With a History of Juvenile Idiopathic Arthritis. (Pubmed Central) -  Nov 27, 2025   
    The patient was treated with adalimumab and had no evidence of active arthritis at other sites...Selective transarterial embolization of the malleolar branch of the anterior tibial artery was therefore performed, resulting in marked improvement in pain and swelling. In conclusion, transarterial embolization proved feasible and led to meaningful short-term clinical benefit, supporting its potential as an adjunctive therapeutic option in carefully selected cases of residual refractory ankle arthritis.
  • ||||||||||  Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
    Review, Journal:  Severe liver injury due to infliximab therapy and adalimumab. (Pubmed Central) -  Nov 27, 2025   
    In contrast with the severe liver injury described in patients treated with infliximab, no cases of acute liver failure due to adalimumab requiring liver transplantation have been reported. However, subacute liver failure due to hepatitis B reactivation have been reported associated with adalimumab therapy and one case of subacute liver failure with adalimumab has been described in a patient without concomitant hepatitis B.
  • ||||||||||  Humira (adalimumab) / AbbVie, methylprednisolone sodium succinate / Generic mfg.
    Journal:  Unmasking Neurosarcoidosis in a Patient With Acute Meningitis Features. (Pubmed Central) -  Nov 27, 2025   
    We report the case of a 32-year-old man with a background history of Crohn's disease treated with Adalimumab who presented with a 10-day history of worsening headache, confusion, and new-onset seizures...After multidisciplinary team review, high-dose intravenous methylprednisolone was commenced, followed by an oral prednisolone taper, leading to significant symptomatic improvement...Early multidisciplinary involvement, systematic exclusion of infection and malignancy, and timely initiation of immunosuppression were critical to achieving a favourable outcome in this case. Clinicians should maintain a high suspicion for neurosarcoidosis in patients presenting with atypical neurological features, as early recognition and treatment may substantially alter prognosis.
  • ||||||||||  Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
    Review, Journal:  Therapeutic Drug Monitoring in Special Circumstances in Inflammatory Bowel Disease. (Pubmed Central) -  Nov 27, 2025   
    These include inflammatory burden, bodyweight, age, disease phenotype, and route of administration, all of which are important considerations for individualising treatment in inflammatory bowel disease. This narrative review explores how special clinical situations-acute severe ulcerative colitis, perianal fistulising Crohn's disease, hypoalbuminaemia, extremes of body composition, pregnancy, paediatrics, and advanced age-alter drug pharmacokinetics and influence the utility and interpretation of therapeutic drug monitoring in inflammatory bowel disease.
  • ||||||||||  Humira (adalimumab) / AbbVie
    Journal:  Experiences of People Living with a Kidney Transplant: A Phenomenological Study. (Pubmed Central) -  Nov 27, 2025   
    The five themes, including (1) having new life and life satisfaction, (2) fear of kidney rejection and complications, (3) gratitude and spiritual practices, (4) concerns for the high cost of healthcare expenses, and (5) patience with self-management and resilience. We suggest that holistic, financial, and culturally congruent care should be implemented among people undergoing kidney transplantation to promote resilience and a longer life.
  • ||||||||||  Journal:  Successful treatment of pustulotic arthro-osteitis with bimekizumab: A case report. (Pubmed Central) -  Nov 25, 2025   
    The patient became afebrile the day after switching to BKZ, and both joint and skin symptoms gradually improved thereafter, along with normalization of laboratory markers. This case highlights the potential utility of BKZ in the treatment of refractory PAO, particularly in cases with systemic inflammation and fever.
  • ||||||||||  Humira (adalimumab) / AbbVie
    Journal:  A Label-Free blocking immunoassay to evaluate Anti-Adalimumab antibody activity in clinical samples. (Pubmed Central) -  Nov 24, 2025   
    The LF-BIA may provide an efficient approach to specifically measure blocking ADAs rather than total ADAs. Alongside with previously reported applications of label-free immunoassays in clinical testing, the LF-BIA highlights a promising area in which label-free technologies such as BLI can play an important role.
  • ||||||||||  Journal:  Tocilizumab as a treatment tool for ROSAH syndrome: a case report. (Pubmed Central) -  Nov 21, 2025   
    Broader clinical studies are needed to confirm efficacy. This case also highlights the importance of including ALPK1 in genetic panels for optic neuropathies, retinal disorders, and unexplained arthropathies to improve diagnosis and treatment strategies.
  • ||||||||||  Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
    PK/PD data, Journal:  STRATIfy-PK SCORE: A predictive tool for identifying pharmacokinetic failure risk in anti-TNF-treated patient. (Pubmed Central) -  Nov 21, 2025   
    This case also highlights the importance of including ALPK1 in genetic panels for optic neuropathies, retinal disorders, and unexplained arthropathies to improve diagnosis and treatment strategies. STRATIfy-PK SCORE allows early identification of patients at high risk of pharmacokinetic failure and may support proactive, personalized TDM strategies to improve clinical outcomes.
  • ||||||||||  Stelara (ustekinumab) / J&J, Humira (adalimumab) / AbbVie
    Journal:  Serum Protein Profiles Differ with Adalimumab and Ustekinumab Treatment in Moderately to Severely Active Crohn's Disease. (Pubmed Central) -  Nov 19, 2025   
    P3
    Although patients receiving either adalimumab or ustekinumab reached similar rates of clinical remission at Week 52, the two therapies resulted in unique serum proteomic expression profiles reflecting mechanistic differences. Long-term treatment data is necessary to understand how differences in therapeutic mechanisms are associated with maintenance of remission and changes in patient reported outcomes in the context of inflammatory biomarkers.
  • ||||||||||  Journal:  Crohn's disease exacerbated by ghost pills of upadacitinib. (Pubmed Central) -  Nov 19, 2025   
    The disease activity was difficult to control with infliximab...She was subsequently introduced to several biologic agents, including adalimumab, ustekinumab, and vedolizumab: All failed to maintain long-term endoscopic and clinical remission...When using an extended-release agent such as UPA in patients with CD, the patient's gastrointestinal condition must be considered. Moreover, appropriate information must be shared with other health care professionals.
  • ||||||||||  Journal, Adverse events:  Interleukin-17 Inhibitors and Early Major Adverse Cardiovascular Events. (Pubmed Central) -  Nov 19, 2025   
    inhibitors (adalimumab or etanercept) for similar indications (psoriasis, psoriatic arthritis, ankylosing spondylitis, or juvenile arthritis), as an active comparator...In this case-time-control study based on a national insurance database, there was no evidence of a significant association between MACEs and the initiation of IL-17(R)A inhibitors, regardless of the individual cardiovascular risk of the patient. However, a modest risk increase cannot be entirely excluded.
  • ||||||||||  Humira (adalimumab) / AbbVie
    Journal:  Risk of Serious Infection With Adalimumab in Hidradenitis Suppurativa Compared With Psoriasis. (Pubmed Central) -  Nov 19, 2025   
    In this cohort study, among adults treated with adalimumab, those with moderate to severe HS had an elevated risk of infection and different infection profiles compared with those with psoriasis. Future research should focus on the impacts of disease severity and treatment regimens on infection risk and develop targeted prevention strategies.
  • ||||||||||  Humira (adalimumab) / AbbVie
    Journal:  Machine learning-accelerated 1H NMR quantification for bioprocess metabolite monitoring in monoclonal antibody production. (Pubmed Central) -  Nov 16, 2025   
    This study proposes a novel NMR spectral analysis strategy based on machine learning, successfully developing rapid quantitative models for 20 key metabolites in adalimumab biosimilar production process...The obtained optimal models for each metabolite exhibited great model performance with regression coefficients (R2) above 0.92 and residual prediction deviation (RPD) values exceeding 3.6. This study provides a reliable tool for intelligent monitoring of mAb production process, which can help ensure bioprocess consistency, improve yield and product quality, and ultimately reduce cultivation costs.
  • ||||||||||  Stelara (ustekinumab) / J&J, Humira (adalimumab) / AbbVie
    Review, Journal:  From reactive to predictive: Advancing biologic dosing in dermatology. (Pubmed Central) -  Nov 14, 2025   
    Model-informed precision dosing represents a paradigm shift in biologic therapy management, moving from standardised to dynamic, patient-centric dosing. By combining real-time monitoring, digital tools, and biological profiling, MIPD has the potential to maximise clinical response, minimise toxicity, and enhance the sustainability of long-term biologic treatment in dermatology.
  • ||||||||||  Bimzelx (bimekizumab-bkzx) / UCB, Humira (adalimumab) / AbbVie, Cosentyx (secukinumab) / Novartis
    Journal:  Towards the development of upgrade criteria for the treatment of hidradenitis suppurativa with biologics. (Pubmed Central) -  Nov 13, 2025   
    A significant proportion of respondents expressed a preference for earlier biologic intervention, especially in cases of severe disease or frequent flares. The findings underscore the need for a consensus statement defining upgrade criteria for biologics as a first-line therapy, potentially improving patient outcomes and reducing healthcare burdens.
  • ||||||||||  Review, Journal:  Management of Erythrodermic Psoriasis with Systemic Therapies: A Systematic Review. (Pubmed Central) -  Nov 13, 2025   
    In the case of contraindications or treatment failure of traditional systemic therapies, among biologic drugs, the rapidity of action, safety, and limited evidence of efficacy are in favor of IL-17 inhibitors and risankizumab. However, the findings we report are limited by the evidence available in current literature, which is characterized by low statistical power.
  • ||||||||||  Humira (adalimumab) / AbbVie
    Journal:  Adalimumab-Associated Hemoptysis. (Pubmed Central) -  Nov 7, 2025   
    Anti-IL17 was the preferred first- and second-line biologic agent used in Malaysia. No abstract available
  • ||||||||||  "Parenchymal CLL Infiltration without Richter Transformation: A case report." (Section 1 (Confex)) -  Nov 5, 2025 - Abstract #DGHO2025DGHO_598;    
    CNS involvement in CLL is rare and poses a diagnostic and therapeutic challenge. Our case underlines the importance in discrimination between RT and CLL for optimal treatment, as well as the significance of brain biopsy in case of elusive findings.The highly atypical presentation of parenchymal brain infiltration could be associated with the underlying rheumatologic disease and exposure to chronic inflammation and immunosuppression.While BTK inhibitors like zanubrutinib have shown promise in CNS lymphomas, further data are needed to assess durability and long-term outcomes in CLL-related CNS disease.